R1 RCM (NASDAQ:RCM) Downgraded to Equal Weight at Stephens

Stephens lowered shares of R1 RCM (NASDAQ:RCM) from an overweight rating to an equal weight rating in a report published on Thursday, Marketbeat reports.

Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed an overweight rating and issued a $20.00 price target on shares of R1 RCM in a research report on Tuesday, July 2nd. Canaccord Genuity Group reaffirmed a buy rating and issued a $15.00 price target on shares of R1 RCM in a research report on Monday, July 22nd. KeyCorp reaffirmed a sector weight rating on shares of R1 RCM in a research report on Wednesday, April 10th. Morgan Stanley reaffirmed an overweight rating and issued a $17.00 price target on shares of R1 RCM in a research report on Monday, July 8th. Finally, Jefferies Financial Group lowered shares of R1 RCM from a buy rating to a hold rating in a research note on Thursday. Ten investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Hold and a consensus price target of $16.02.

R1 RCM Trading Down 1.0 %

R1 RCM stock traded down $0.14 during trading hours on Thursday, hitting $13.91. The company had a trading volume of 4,275,155 shares, compared to its average volume of 3,678,047. The firm has a market cap of $5.86 billion, a P/E ratio of -175.63 and a beta of 0.85. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 1.79. R1 RCM has a 1 year low of $8.87 and a 1 year high of $18.22. The company has a 50-day moving average price of $12.66 and a two-hundred day moving average price of $12.34.

R1 RCM (NASDAQ:RCM) last released its quarterly earnings data on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The company had revenue of $603.90 million during the quarter, compared to analysts’ expectations of $612.88 million. R1 RCM had a negative net margin of 1.39% and a negative return on equity of 1.16%. R1 RCM’s revenue for the quarter was up 10.7% on a year-over-year basis. On average, sell-side analysts anticipate that R1 RCM will post -0.2 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RCM. Privium Fund Management UK Ltd acquired a new stake in shares of R1 RCM in the second quarter worth $502,000. CIBC Asset Management Inc acquired a new stake in shares of R1 RCM in the second quarter worth $149,000. BW Gestao de Investimentos Ltda. increased its stake in shares of R1 RCM by 14.9% in the second quarter. BW Gestao de Investimentos Ltda. now owns 1,027,220 shares of the healthcare provider’s stock worth $12,902,000 after acquiring an additional 133,324 shares during the period. Pentwater Capital Management LP acquired a new stake in shares of R1 RCM in the second quarter worth $2,512,000. Finally, Intact Investment Management Inc. acquired a new stake in shares of R1 RCM in the second quarter worth $621,000. Institutional investors and hedge funds own 61.10% of the company’s stock.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.